Scrub Typhus Management Protocols 2026

Introduction and Clinical Suspicion

Scrub typhus, caused by Orientia tsutsugamushi, is the most prevalent rickettsial infection in India and a leading etiology of pediatric acute encephalitis syndrome (AES) in endemic zones.
Clinical suspicion relies on identifying an acute febrile illness accompanied by an eschar (a black necrotic lesion at the chigger bite site, present in 7–97% of cases), maculopapular rash, lymphadenopathy, and hepatosplenomegaly.
Disease progression to acute respiratory distress syndrome (ARDS), meningoencephalitis, and multi-organ dysfunction syndrome (MODS) occurs in nearly one-third of hospitalized children if treatment is delayed.

Diagnostic Guidelines

Empirical Therapy: Protocols mandate immediate initiation of empirical antibiotics based purely on clinical suspicion; treatment must never be delayed pending serological or PCR confirmation.
Recommended Investigations: Diagnosis is confirmed via IgM ELISA or PCR at higher-level centers.
Obsolete Tests: The Weil-Felix test is officially classified as obsolete and should not guide clinical decision-making.

First-Line Pharmacological Management

The Indian Academy of Pediatrics (IAP) and the Ministry of Health and Family Welfare (MoHFW) 2025-2026 operational updates firmly establish the following pharmacological protocols:

Drug	Recommended Dosage	Duration	Clinical Remarks
Doxycycline (Drug of Choice)	4.4 mg/kg/day divided q12h (Oral/IV). Maximum 200 mg/day.	Minimum 5–7 days (or until afebrile for $\geq$ 3 days).	Recommended for all age groups, including children <8 years. Short courses (<7–10 days) pose negligible risk of dental staining.
Azithromycin (Alternative)	10 mg/kg on day 1, followed by 5 mg/kg OD.	3–5 days (or 5–7 days if given 10 mg/kg OD).	Reserved for doxycycline intolerance; not routinely preferred over doxycycline in standard pediatric cases.
Chloramphenicol	Weight-based dosing.	Individualized.	Reserved strictly for highly specific, refractory clinical scenarios.

Management of Severe Disease and Complications

Intravenous Monotherapy: IV doxycycline monotherapy is generally sufficient for meningoencephalitis and severe scrub typhus presentations.
Combination Therapy: Based on landmark 2023-2026 trial evidence, combination therapy (IV Doxycycline + Azithromycin) is strongly recommended for refractory shock, ARDS, or severe MODS to achieve superior and faster defervescence.
Immunomodulation: The use of Intravenous Immunoglobulin (IVIG) and dexamethasone is actively explored as a rescue adjunct in refractory cases presenting with severe multi-organ failure.

Supportive Care and Prevention

Hemodynamic Stabilization: Aggressive fluid resuscitation must be balanced carefully to avoid fluid overload, which exacerbates ARDS and cerebral edema risks.
Vector Control: No vaccine is currently available. Prevention relies entirely on active rodent control, reducing mite exposure through protective clothing, and community education integrated under National Center for Vector Borne Diseases Control (NCVBDC) frameworks.